doi: 10.1136/gutjnl-2021-324243 63
The practical takeaway If your physician cites animal studies as the primary reason to avoid GLP-1 therapy while breastfeeding, ask about the human lactation data that has since been published
GLP-1 drugs are a clear example: They target a single signaling system yet can help improve obesity, diabetes, heart disease and kidney disease all at once
Davinelli, S
Apovian, M.D., co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, points out that its tough to compare these trials because they may have differences like how long the subjects are on the drugs
A 2023 analysis of the SUSTAIN and PIONEER trials published in Cardiovascular Diabetology showed significant reductions in high-sensitivity C-reactive protein, a marker of systemic inflammation, among patients taking semaglutide